echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JAHA: Dual antiplatelet therapy of cilostazol in patients with stroke and intracranial artery stenosis

    JAHA: Dual antiplatelet therapy of cilostazol in patients with stroke and intracranial artery stenosis

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In patients with intracranial arterial stenosis, the dual antiplatelet therapy (DAPT) in the prevention of recurrent stroke with a single antiplatelet therapy (SAPT) long-term benefits in the prevention of recurrent stroke has not been clear
    .

    Prevent stroke

    Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, the researchers aimed to compare the DAPT joint cilostazol and clopidogrel or aspirin efficacy in patients with intracranial arterial stenosis and SAPT clopidogrel or aspirin And safety
    .

    Heart blood vessels

    These patients were recruited into the antiplatelet combined with cilostazol stroke prevention study, a randomized controlled trial conducted in Japanese patients at high risk of ischemic stroke
    .

    Researchers compared DAPT and SAPT in at least 50% of patients with ischemic stroke and symptomatic or asymptomatic intracranial arterial stenosis and bleeding events
    .


    The patients were divided into two groups: 275 were assigned to receive DAPT, and 272 patients were assigned to receive SAPT


    Myocardial infarction

    It can be seen that DAPT using cilostazol is superior to SAPT using clopidogrel or aspirin in preventing stroke recurrence and vascular events, and does not increase the risk of bleeding in patients with intracranial artery stenosis after stroke
    .

    DAPT using cilostazol is superior to SAPT using clopidogrel or aspirin in preventing stroke recurrence and vascular events, and does not increase the risk of bleeding in patients with intracranial artery stenosis after stroke
    .


    Original source:

    Original source:

    Shinichiro Uchiyama.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.